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Abstract
Background: Human Papillomavirus (HPV) genotype distribution varies according to the method of assessment
and population groups. This study analyzed type-specific HPV infections among women ranging from 14–95 years
old, displaying normal and abnormal cytology, from São Paulo and Barretos cities, Brazil.
Methods: Women found positive for High Risk-HPVs DNA by either the Hybrid Capture 2 (HC2) or Cobas HPV Test
(n = 431) plus a random sample of 223 negative by both assays and 11 samples with indeterminate results,
totalizing 665 samples, were submitted to HPV detection by the PapilloCheck test. Cytological distribution included
499 women with a cytological result of Negative for Intraepithelial Lesion or Malignancy and 166 with some
abnormality as follows: 54 Atypical Squamous Cells of Undetermined Significance; 66 Low-Grade Squamous
Intraepithelial Lesion; 43 High-Grade Squamous Intraepithelial Lesion and 3 (0.5 %) Invasive Cervical Cancer.
Results: From the 323 samples (48.6 %) that had detectable HPV-DNA by the PapilloCheck assay, 31 were HPV
negative by the cobas HPV and HC2 assays. Out of these 31 samples, 14 were associated with HR-HPVs types while
the remaining 17 harbored exclusively low-risk HPVs. In contrast, 49 samples positive by cobas HPV and HC 2
methods tested negative by the PapilloCheck assay (19.8 %). Overall, the most frequent HR-HPV type was HPV 16
(23.2 %), followed by 56 (21.0 %), 52 (8.7 %) and 31 (7.7 %) and the most frequent LR-HPV type was HPV 42 (12.1 %)
followed by 6 (6.2 %). Among the HR-HPV types, HPV 56 and 16 were the most frequent types in NILM, found in 19.
1 and 17.7 % of the patients respectively while in HSIL and ICC cases, HPV 16 was the predominant type, detected
in 37.2 and 66.7 % of these samples.
Conclusions: In the population studied, HPV 16 and 56 were the most frequently detected HR-HPV types. HPV 56
was found mainly in LSIL and NILM suggesting a low oncogenic potential. HPV 16 continues to be the most
prevalent type in high-grade lesions whereas HPV 18 was found in a low frequency both in NILM and abnormal
smears. Surveillance of HPV infections by molecular methods is an important tool for the development and
improvement of prevention strategies.
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Background
Two hundred different HPV types, classified into 49 spe-
cies, are currently recognized by the International HPV
Reference Center [1]. From these, about 40 are found in
the female genital tract [2] and can be divided, according to
their ability to generate malignancies, into low-risk types
(LR-HPV) (e.g. HPV 6 and 11) which are rarely detected in
high grade cervical lesions (HSIL) but produces the major-
ity of genital warts [3, 4] and high-risk types (HR-HPV),
which cause lesions with potential for oncogenic progres-
sion (e.g. HPV 16 and 18) [5]. Longitudinal studies have
shown that individual HPV types grouped under the HR-
HPV class differ enormously in their oncogenic potential
and the pace in which they may drive the evolution of
high-grade premalignant lesions to cervical cancer. Know-
ledge on the distribution of individual HPV types in differ-
ent geographical areas is fundamental for the optimization
of cervical cancer preventive strategies such as vaccination
and HPV-DNA primary screening, which should take into
consideration the local contribution of HPV types [6].
The majority of HPV infected women will never de-
velop cancer since most HPV infections are transient
and asymptomatic. As expected, HPV is more prevalent
in young sexually active women (18 to 30 years) [7],
decaying with aging. However, a second peak of HPV
has been described after menopause in some studies [8],
but was not verified in larger cohorts worldwide, except
for Africa and Central America [7]. HPV persistence and
progression from infection to disease vary according to
the virus genotype, even among HR-HPV types [9]. An-
other important factor for disease progression seems to
be the age; women with an HPV genital infection and
older than 40 years have much higher risk of progression
to cervical cancer than younger women [10].
Invasive Cervical Cancer (ICC) is worldwide the third
most frequent cancer among women [11]. In Brazil, ICC
is preceded only by non-melanoma skin cancer and breast
cancer. According to the Brazilian National Cancer Insti-
tute, 16,340 new cases are expected to occur in 2016 with
an estimated incidence of 15.85 cases per 100,000 women.
In São Paulo State, where the present study was con-
ducted, the estimated incidence for 2016 was of 9.50 per
100,000 women, in contrast to, for instance, another Bra-
zilian city, Manaus located in the North region, where an
alarming projection of 53.73 cases per 100,000 women,
not adjusted by age, was made [12].
The distribution and prevalence of the HPV genotypes
vary with the grade of cervical disease, age and the geo-
graphical location of the patients [8, 13–15]. Prevalence
of HPV 16 and 18 increases in parallel to the severity of
the lesion [16–18] being associated to approximately
70 % of the ICC cases worldwide but are also the most
frequent types observed in women with normal cytology
[7]. In a meta-analysis of 1 million women with normal
cytological findings, HPV18 was found in many regions
as the second most frequent [19], also verified in some
Brazilian studies [20–22]. Notwithstanding HPV 31 oc-
cupies the second position in frequency in Europe and
HPV 52 in Africa, pointing to the importance of other
HR-types non 16/18 in certain regions [19]. Illustrating
the geographical variability, in Brazil, HPVs 31 and 33
are the second most prevalent types [23, 24] among se-
lected populations, respectively in the Northeast and
Central regions. Surprisingly, HPV 66 was detected in
22 % of the HPV positive samples from Campo Grande,
Mato Grosso do Sul, [25] and HPV 58 was the most fre-
quent type (19.8 %) in HIV-infected women followed by
HPV 53 (15.5 %) in the Southeast region [26].
As a result of accumulated knowledge over the past
three decades on the causal relationship between HPV
infection and ICC, detection of the viral DNA became
an attractive approach to identify women at risk for de-
veloping ICC [27, 28]. Evidence from randomized trials
now supports the incorporation of screening methods
that clearly focus on the detection of the HPV genome
[29] since there is overwhelming evidence that this is
more sensitive than cytology for identifying CIN3, the
true premalignant precursor of ICC [30–32]. Investigat-
ing HPV genotypic distribution and disease-association
became an important tool in epidemiological studies,
further supporting vaccine and screening tests develop-
ment and improvement, by ensuring their coverage and
effectiveness [33, 34].
Since June 2013, the Brazilian Ministry of Health has an-
nounced the decision to introduce the quadrivalent HPV
vaccine in the national immunization program, the vaccin-
ation schedule (0 and 6 months) was updated in January
2016. From 2014, this vaccine was offered to girls and ado-
lescents 11–13 years old and from 2015 for adolescents be-
tween 9 and 11 years [35]. In this context, HPV genotyping
may be an essential tool to assess the program effectiveness
by identification of the genotypic profile pre and post HPV
vaccination.
PapilloCheck assay is a robust method for HPV geno-
typing, which is based on PCR amplification of a fragment
of approximately 350 bp from the E1 region of HPV ge-
nomes, using broad-spectrum consensus primers, allow-
ing the simultaneous detection and genotyping of 24
different HPV types by DNA chip technology including
low-risk HPVs [36].
We aimed to uncover the HPV type-distribution
hiding under an HPV-HR result in the HC2 test or
the 12 HR-HPVs cocktail in the Cobas HPV test to
analyze the HPVs genotype distribution in women
undergoing routine cervical cancer screening and
women with a previous abnormal Pap test in São
Paulo and Barretos cities and their correlation to
cytological results and age groups.
Martins et al. Virology Journal  (2016) 13:138 Page 2 of 9
Methods
Study population
Specimens were collected in between October, 2009 and
April, 2011, in two reference centers of São Paulo State,
Brazil: Hospital das Clínicas from the São Paulo Medical
School, Universidade de São Paulo and Hospital de Cân-
cer de Barretos. Participants, with age ranging from 14
to 95 years, average 43 yo, median 43yo (SD = ±14 yo),
consisted of 403 women undergoing routine screening
(n = 156 from São Paulo and 247 from Barretos), in
addition to 262 referral women with a previous abnor-
mal Pap test in the year preceding study enrollment (163
from São Paulo and 99 from Barretos). A cervical sample
was obtained and processed as described elsewhere [14].
Briefly, all samples were submitted to Cobas 4800
HPV (Roche Molecular Systems, Pleasanton, CA, USA)
and the Hybrid Capture 2 (HC2, Qiagen, Hilden,
Germany) assays. Only the HR-HPV cocktail probe was
employed on the HC2 testing. Samples from women
found positive for high-risk HPVs DNA by either the
HC2 or Cobas HPV (n = 431) were submitted to HPV
genotyping by the PapilloCheck assay (Greiner Bio-One,
Frickenhausen, Germany) [14] plus a random sample of
223 negative by both assays and 11 samples with inde-
terminate or invalid results, totalizing 665 samples as
shown in Table 1.
Molecular tests
Cervical scrapes obtained by the SurePath collection kit
(BD SurePath ™ - TriPath, Burlington, NC, EUA) and
preserved in liquid cytology medium were transported
to the lab where DNA was extracted using the QIAamp
DNA Mini Kit (Qiagen, Gaithersburg, USA), according
to manufacturer’s instructions. For each reaction, 5 μL
of DNA eluate was used in the PapilloCheck assay. Spec-
imens containing the target DNA are hybridized to spe-
cific oligonucleotide probes immobilized on a DNA chip
and detected by the binding of a Cy5-dUTP labeled
oligonucleotide probe to the tag sequence. The DNA
chip is scanned by the CheckScanner apparatus at wave-
lengths of 532 and 635 nm. This test detects HPV geno-
types 6, 11, 16, 18, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51,
52, 53.56, 58, 59, 66, 68, 70, 73 and 82. In addition, hu-
man ADAT1 gene (adenosine deaminase, tRNA specific
1) is used as an internal control to assess the quality of
the DNA [36].
Cytology
Six hundred sixty five smears were examined by staff
cytopathologists at both institutions and classified ac-
cording to the Bethesda system [37]: NILM (Negative
for Intraepithelial Lesion or Malignancy), ASC-US
(Atypical Squamous Cells of Undetermined Signifi-
cance), ASC-H (Atypical squamous cells – cannot ex-
clude HSIL), LSIL (Low-Grade Squamous Intraepithelial
Lesion); HSIL (High-Grade Squamous Intraepithelial Le-
sion) and ICC (Invasive Cervical Cancer). For analysis
purposes in this study ASCUS and ASC-H were grouped
under ASCUS class.
Statistical analyses
HPV genotype distribution analyses were performed
using GraphPad Prism version 5.0. The x2 and p trend
test were used to evaluate statistical significance between
genotype, cytological diagnosis and age. For all analyses,
a p < 0.05 was considered statistically significant.
Results
Liquid based cytology
Cytological diagnosis of these samples included 499
(75 %) women with negative cytology (NILM) and 166
(25.0 %) with some cytological abnormality as follows:
54 (8.1 %) ASCUS; 66 (9.9 %) LSIL; 43 (6.5 %) HSIL and
3 (0.5 %) ICC.
When stratified by age group, LSIL was less frequent
in women older than 45 years old (p trend = 0.01),
whereas HSIL was more frequent (p trend = 0.03). All 3
ICC cases were found in women older than 45 years: 48,
52 and 84 years old.
HPV genotype distribution
Among the 665 samples analyzed 323 (48.6 %) were
HPV positive by the PapilloCheck assay. Single type in-
fection was observed in 65 % (210/323) of them, while
59 (18 %) had co-infection by 2 HPV types, 34 (11 %) by
three, 14 (4 %) by four and 6 (2 %) by five or more types.
The frequency of HPV infection decreased with aging (p
trend <0.001); in women under 31 years old the preva-
lence of HPV DNA was 58.2 % (92/158) decreasing to
52.3 % (116/222) in women between 31 and 45 years
and 40.4 % (115/285) in women older than 45 years old.
The most frequent HR-HPV type among HPV positive
women was 16 (23.2 %), followed by 56 (21.0 %), 52
(8.7 %), 31 (7.7 %), 53 (7.7 %), 51 (7.4 %), 39, 59 and 66
(6.5 % each), 33 (5.3 %), 58 (5 %), 18 (5 %), 82 (4 %), 45
and 70 (4 %) each, 68 (3.4 %), 73 (2.5 %) and 35 (2.5 %).
Table 1 Distribution of samples according to prior molecular
testing results
HC2
Cobas
4800
Negative Positive Indet/Inva Total
n n n n
Negative 223 68 - 291
Positive 116 247 - 363
Indet/Inva - - 11 11
Total 339 315 11 665
Legend: aIndet/Inv: Indeterminate or invalid result
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The frequency of LR- HPV types was: 42 (12.1 %), 6
(6.2 %), 44 (4.3 %), 43 (4 %), 40 (2.8 %) and 11 (1.5 %).
No association between LR-HPV and HR-HPV types
with age group was observed.
When stratified by women undergoing routine screen-
ing and those with a previous abnormal Pap test (refer-
ral), HPV 16 was detected more often in referral than in
the screening group; 14.9 % vs 8.9 %. This was also ob-
served for HPV 56, the second most common genotype
in both groups, found in 13.7 and 7.9 % respectively.
Table 2 shows the distribution of the more frequent HR-
HPV genotypes in both groups.
Comparing the HPV result obtained by the Papillo-
Check to the cytology diagnosis, we found 41.8 % (209/
499) of HPV positive results among women with nega-
tive cytology; 55.6 % (30/54) ASCUS; 80.3 % (53/66)
LSIL; 67.4 % (29/43) HSIL and 100 % (3/3) among
women with ICC. Eight HSIL cases, 18.6 % (8/43) were
positive either by Hybrid Capture 2 (HC2), Cobas HPV
or both, while negative for the Papillocheck assay,
whereas in the three ICC cases HPV was detected by all
three methods.
HPV 56 and HPV 16 were the most frequent in nega-
tive cytology being found in 19.1 % (40/209) and 17.7 %
(37/209) of the patients, respectively. In LSIL cases,
HPV 56 was the most frequent type present in 28.8 %
(19/66), while in HSIL and ICC cases, HPV 16 was the
predominant type, detected in 37.2 % (16/43) and 66.7 %
(2/3) of these samples, respectively whilst, the third ICC
case harbored HPV 33. Distribution of HPV types ac-
cording to the cytological diagnosis is shown in Fig. 1.
Concerning samples that showed negative results in
molecular screening by HC2 and Cobas HPV on the ori-
ginal study, 13.9 % (31/223) were HPV positive by the
Papillocheck. Of these, 54.8 % (17/31) were positive for
LR-HPV, whereas 45.2 % (14/31) were associated with
HR- HPVs types 16, 33, 39, 51, 53, 56, 58, 59, 66, 68, 70
or 73. In contrast, 49 samples positive by both Cobas
HPV and HC 2 methods tested negative by the Papillo-
Check assay (19.8 %; 49/247).
The two HR-HPV types found more frequently in all
ages from the screening group were HPV 16 and 56.
HPV 16 was observed in 15.5 % (15/97) of samples from
women under 31 years and in 7.7 % (14/183) of samples
from women older than 45 years, followed by HPV-56
that was detected in 9.3 % (9/97) of the patients under
31 years and in 6.0 % (11/183) of the older than 45 years.
In samples from women aged 31–45 years old, the most
frequent HR-HPV type was HPV 56 (9.8 %; 12/123),
followed by HPV 16 (5.7 %; 12/123). The most frequent
HPV types according to age groups are depicted in
Fig. 2.
When HR-HPV genotypes are clustered in HPV spe-
cies according to the classification of de Villiers et al.
[38], it may be observed that the most common species
were alpha-9 and alpha-6, both composed exclusively of
high-risk HPVs; (16, 31, 33, 35, 52, 58) and (53, 56, 66)
respectively, followed by species alpha-7, alpha-1, alpha-
10, alpha-5, alpha-8 and alpha-11 (Fig. 3).
Discussion
In the present study, the specimens analyzed were
enriched from a group of HPV positive samples and a
random subsample of specimens displaying HPV nega-
tive molecular testing results, as described above. Thus,
it has to be considered that this rate of HPV infection
does not represent the true prevalence in women sub-
mitted to cervical cancer screening, in whom HR-HPV
DNA was detected in about 9 % of subjects under rou-
tine screening, nor the prevalence in the referral group,
of 24 % in women with a previous abnormal Pap test
[14].
Differences in the prevalence and distribution of HPV
types worldwide have been observed in several studies
[1, 39], and can be related to the complex interaction be-
tween distinct HPV types with host immunogenetic fac-
tors, age, geographic location of the patients or use of
different sets of primers in HPV PCR and genotyping as-
says used in these studies [40, 41].
HPV 16 was the most frequent type in the present
series as found in almost all screening population stud-
ies, irrespective of the study design [42–44]. An interest-
ing finding of this study was that HPV 56 was the
second most common type, as previously reported by
Levi and colleagues [14], confirming the results of Bruno
et al. [15] in a study conducted in women from the state
of Bahia, Brazil, where it was detected in 14 % of the
cervical samples. This finding was not verified in other
Table 2 Frequency of HR-HPVs in screening (n = 403) and refer-
ral (n = 262) groups as determined by the Papillocheck assay
HPV type referral n (%) HPV type screening n (%)
16 39 (14.9) 16 36 (8.9)
56 36 (13.7) 56 32 (7.9)
31 17 (6.5) 52 18 (4.5)
39 13 (5.0) 53 15 (3.7)
66 13 (5.0) 59 12 (3.0)
58 13 (5.0) 51 11 (2.7)
51 12 (4.6) 33 9 (3.4)
52 10 (3.8) 45 9 (3.4)
53 10 (3.8) 31 8 (2.0)
82 10 (3.8) 18 8 (2.0)
18 9 (3.4) 39 7 (1.7)
59 9 (3.4) 66 7 (1.7)
Other 88 (33.6) Other 67 (16.6)
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studies performed in Brazil; therefore, presence of HPV
56 in such a high frequency demands further
investigation.
In the current study, HPV 56 was the most frequent
type among HPV+ women bearing NILM and LSIL cy-
tology, found respectively in 19.1 and 28.8 % of these
samples. In contrast Oliveira-Silva et al. [22] studied 84
NILM samples from Brazilian women reactive by Hybrid
Capture II, observing only one HPV 56 infection (0.8 %)
while Martin et al. [45], in Spain, reported the presence
of HPV 56 in 2.4 and 7.9 % of their NILM and LSIL cy-
tology specimens.
In fact, other studies using PapilloCheck assay re-
ported rates of HPV 56 above the expectation [15, 46],
which may be attributed to an increased sensitivity of
the test for this particular type or, alternatively, reduced
specificity [36]. Undertaking other molecular techniques
such as type-specific PCR or DNA direct sequencing of
these samples could dismiss the potential lack of specifi-
city of this method.
Fig. 1 Frequency of individual HPV types according to cytological diagnosis
Fig. 2 Distribution of HPV genotypes by age (screening group, n = 403)
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In this study, HPV 16 was the predominant type
found in 38.1 and 66.7 % of the HPV+ HSIL and ICC
cases respectively. These findings corroborate the re-
sults of a systematic review and meta-analysis in
Latin America and the Caribbean including 2446
cases of HSIL and 5540 of ICC that reported HPV 16
as the most frequent type, verified in 46.5 % of HSILs
and 53.2 % of ICC cases [47]. In another study con-
ducted in São Paulo, samples from histologically con-
firmed invasive cervical cancer (n = 175) also harbored
HPV 16 as the most frequent type (77.6 %), followed
by HPV 18 (12.3 %), HPV 31 (8.8 %), HPV 33 (7.1 %)
and HPV 35 (5.9 %) [48].
Detection of of LR-HPV types in the current study is ex-
plained by the inclusion of probes for these genotypes in
the PapilloCheck assay, depicting them when present in co-
infections with the HR-HPV genotypes, or in single type in-
fections in the HPV screening (Cobas-/HC2-) negative
group. Regarding the LR-HPV types, HPV 42 was the most
common as observed in other studies using the same
method of genotyping [15, 49, 50]. This higher frequency of
HPV 42 compared to other low risk types could potentially
be attributed to specific features of the Papillocheck assay,
as observed for HPV 56.
Currently, HPV DNA testing has been incorporated
into cervical cancer screening algorithms to triage
cases with indeterminate cytologic results (ASC-US)
[51]; clinical follow-up after treatment, monitoring of
patients without cytological lesions or only minor le-
sions that were identified by colposcopy; resolution of
discordant results of cytology, colposcopy, or hist-
ology [52, 53]; or as an stand-alone primary screening
tool [54, 55]. As seen in this study, HPV DNA is de-
tected in the majority of the precursor lesions or ICC
[56]. Several HPV tests are available in the market,
and we evaluated methodologies with different targets
and principles, nevertheless no test is infallible and
false-negative results may possibly occur [57].
In the current study, HPV DNA was not detected in
32.6 % of HSIL samples. This rate is higher than found
by Guo et al. [58], whom reported that 13.6 % of their
HSIL cases displayed a negative HPV-DNA molecular
test. False-negative results may be due to a low burden
of HPV DNA, presence of a new type of HPV not tar-
geted by the method used, inadequate sampling, cyto-
logical and histopathological missclassification or might
have been the result of methodological or reproducibility
errors [59, 60]. The fact that the E1 region, targeted by
the Papillocheck assay, is located next to the E2 region
in the HPV genome, could render it more vulnerable to
partial deletion, that often occurs during the HPV DNA
integration into the host cell DNA [36] verified on more
advanced squamous intraepithelial lesions.
When stratified by age group, women under 31 years
old had the highest HPV frequency which mostly repre-
sents transient infections [61]. However, for women aged
31 years old or more, test positivity may indicate persist-
ent infection, which would require more intense moni-
toring, when molecular testing could be more effective.
Multiple infections were detected in 35 % of sam-
ples, and were more frequent in women under
31 years old. This observation is consistent with
others studies [45, 62], and suggests that it may be
associated to more intense sexual activity in younger
women. It is well known that the prevalence of HPV
infection and the occurrence of multiple infections
decrease with an increase in age [63, 64].
Current US guidelines recommend genotyping only
for HPV 16 and 18, and detection of either of these two
HPV types is sufficient to warrant direct referral to col-
poscopy, avoiding additional triage methods. However,
some studies suggested that it may be also clinically
Fig. 3 Frequency of HPV genotypes among HPV+ samples as grouped by phylogenetic species
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useful to identify other HPV types such as HPV 31, 33,
33/58 (combined), which showed comparable or in-
creased risk for the development of CIN 2+ [65–67].
Conclusions
The nonavalent HPV vaccine appears to be safe and ef-
fective in preventing persistent infection and precancer-
ous lesions associated with HPV types 16/18/31/33/45/
52/58, as well as genital warts related to HPV types 6
and 11 [68]. Moreover, the currently available HPV vac-
cines have shown partial cross-protection against HR-
HPV types [69] by alpha7/alpha9 high-risk HPV species
but it should not provide cross-protection against HPV
56, which is an alpha 6 group species. Although HPV 56
was a common finding in our study, especially in cases
of NILM and LSIL, it was not found in ICC and in HSIL
cases suggesting lower oncogenic potential, corroborat-
ing the data from de Oliveira et al. [48], who did not find
HPV 56 in any of the 175 ICC cases from São Paulo.
The prevalence and genotype distribution of human
papillomavirus (HPV) provides the basis for designing
HPV prevention programs. HPV types 53, 66, 68, 70, 73
and 82 included in the Papillocheck assay and other
types such as HPVs 26 and 67 have been rarely but con-
sistently identified as single HPV infections in about 3 %
of cervical cancer tissues [70]. To describe the genotypic
profile pre and post HPV immunization is an important
step in prevention strategies for cervical cancer and fur-
ther studies are needed to elucidate the potential role of
these HPV types in the development of malignancies,
eventually justifing their inclusion in new HPV vaccine
formulations. Such decisions have to include careful esti-
mation of effectiveness and cost-benefit.
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